BioCentury | Oct 31, 2011
Finance

Morgenthaler splits

...for an undisclosed upfront payment plus potential milestones. In December, Morgenthaler sold hypertension device play Ardian...
...than $1.1 billion. The firm also invests in IT and cleantech. The firm's exits include Ardian...
BioCentury | Dec 13, 2010
Clinical News

Symplicity Catheter System: Phase II data

...open-label, international Phase II Symplicity HTN-2 trial in 106 patients with uncontrolled hypertension showed that Ardian's...
...is acquiring the 89% of Ardian it does not already own (see BioCentury, Dec. 6). Ardian...
BioCentury | Dec 6, 2010
Finance

Devices target drug space

...with medical device alternatives paid off last month, with the sale of hypertension device play Ardian...
...a $47 million venture round for Ardian in 2009 and held 11% of the company. Ardian's...
...device portfolio companies either through entrepreneurs-in-residence or via two incubators: The Foundry and ForSight Labs. Ardian...
BioCentury | Dec 6, 2010
Company News

Ardian, Medtronic deal

...89% of Ardian it does not already own for $800 million in cash up front. Ardian...
...to the annual revenue growth associated with renal denervation products through Medtronic's fiscal year 2015. Ardian's...
...deal is expected to close in Medtronic's fiscal 3Q11, which ends on Jan. 29, 2011. Ardian...
BioCentury | Nov 24, 2010
Company News

Medtronic to acquire Ardian

...Medtronic Inc. (NYSE:MDT) will acquire the 89% of Ardian Inc. (Mountain View, Calif.) it does not...
...Mountain View, Calif.) it does not already own for $800 million in cash up front. Ardian...
...to the annual revenue growth associated with renal denervation products through Medtronic's fiscal year 2015. Ardian's...
BioCentury | Apr 6, 2009
Clinical News

Symplicity Catheter System: Phase I data

...of Cardiology meeting in Orlando. Symplicity Catheter System has received CE Mark approval in Europe. Ardian...
Items per page:
1 - 6 of 6
BioCentury | Oct 31, 2011
Finance

Morgenthaler splits

...for an undisclosed upfront payment plus potential milestones. In December, Morgenthaler sold hypertension device play Ardian...
...than $1.1 billion. The firm also invests in IT and cleantech. The firm's exits include Ardian...
BioCentury | Dec 13, 2010
Clinical News

Symplicity Catheter System: Phase II data

...open-label, international Phase II Symplicity HTN-2 trial in 106 patients with uncontrolled hypertension showed that Ardian's...
...is acquiring the 89% of Ardian it does not already own (see BioCentury, Dec. 6). Ardian...
BioCentury | Dec 6, 2010
Finance

Devices target drug space

...with medical device alternatives paid off last month, with the sale of hypertension device play Ardian...
...a $47 million venture round for Ardian in 2009 and held 11% of the company. Ardian's...
...device portfolio companies either through entrepreneurs-in-residence or via two incubators: The Foundry and ForSight Labs. Ardian...
BioCentury | Dec 6, 2010
Company News

Ardian, Medtronic deal

...89% of Ardian it does not already own for $800 million in cash up front. Ardian...
...to the annual revenue growth associated with renal denervation products through Medtronic's fiscal year 2015. Ardian's...
...deal is expected to close in Medtronic's fiscal 3Q11, which ends on Jan. 29, 2011. Ardian...
BioCentury | Nov 24, 2010
Company News

Medtronic to acquire Ardian

...Medtronic Inc. (NYSE:MDT) will acquire the 89% of Ardian Inc. (Mountain View, Calif.) it does not...
...Mountain View, Calif.) it does not already own for $800 million in cash up front. Ardian...
...to the annual revenue growth associated with renal denervation products through Medtronic's fiscal year 2015. Ardian's...
BioCentury | Apr 6, 2009
Clinical News

Symplicity Catheter System: Phase I data

...of Cardiology meeting in Orlando. Symplicity Catheter System has received CE Mark approval in Europe. Ardian...
Items per page:
1 - 6 of 6